NO314486B1 - Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform - Google Patents

Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform Download PDF

Info

Publication number: NO314486B1
Authority: NO; Norway
Prior art keywords: phenylalanine; lofepramine; preparation; tyrosine; antidepressant
Prior art date: 1994-10-05

Application number

NO19971539A

Other languages

English (en)

Norwegian (no)

Other versions

NO971539L (no

NO971539D0 (no

Inventor

Cari Loder

Original Assignee

Cari Loder

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-05

Filing date

1997-04-04

Publication date

2003-03-31

1994-10-05 Priority claimed from GB9420116A external-priority patent/GB9420116D0/en

1995-04-26 Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en

1997-04-04 Application filed by Cari Loder filed Critical Cari Loder

1997-04-04 Publication of NO971539L publication Critical patent/NO971539L/no

1997-04-04 Publication of NO971539D0 publication Critical patent/NO971539D0/no

2003-03-31 Publication of NO314486B1 publication Critical patent/NO314486B1/no

Links

COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 title claims abstract description 43
201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 18
239000003814 drug Substances 0.000 title claims abstract description 10
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title claims abstract description 9
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 title claims abstract description 9
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title claims abstract description 9
238000011282 treatment Methods 0.000 title claims description 18
239000000935 antidepressant agent Substances 0.000 title claims description 17
229940005513 antidepressants Drugs 0.000 title claims description 14
230000001430 anti-depressive effect Effects 0.000 title claims description 12
239000002552 dosage form Substances 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 7
230000003210 demyelinating effect Effects 0.000 title claims description 5
229960002813 lofepramine Drugs 0.000 claims description 26
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 26
229960005190 phenylalanine Drugs 0.000 claims description 24
239000011782 vitamin Substances 0.000 claims description 9
229930003231 vitamin Natural products 0.000 claims description 9
235000013343 vitamin Nutrition 0.000 claims description 9
229940088594 vitamin Drugs 0.000 claims description 9
150000003722 vitamin derivatives Chemical class 0.000 claims description 9
238000002347 injection Methods 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
229940024606 amino acid Drugs 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
229960000836 amitriptyline Drugs 0.000 claims description 4
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
229960004801 imipramine Drugs 0.000 claims description 4
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 4
229960004441 tyrosine Drugs 0.000 claims description 4
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 3
YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims description 3
QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 3
BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 3
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 3
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 3
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 3
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 claims description 3
229960004606 clomipramine Drugs 0.000 claims description 3
150000001875 compounds Chemical class 0.000 claims description 3
229960003914 desipramine Drugs 0.000 claims description 3
229960005426 doxepin Drugs 0.000 claims description 3
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 3
229960004090 maprotiline Drugs 0.000 claims description 3
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 3
229960003955 mianserin Drugs 0.000 claims description 3
229960004644 moclobemide Drugs 0.000 claims description 3
YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 3
229960001158 nortriptyline Drugs 0.000 claims description 3
229960001779 pargyline Drugs 0.000 claims description 3
-1 pheneizine Chemical compound 0.000 claims description 3
229960002601 protriptyline Drugs 0.000 claims description 3
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 3
229960003741 tranylcypromine Drugs 0.000 claims description 3
OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 claims description 3
229960002431 trimipramine Drugs 0.000 claims description 3
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 3
229960004688 venlafaxine Drugs 0.000 claims description 3
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
229960001255 viloxazine Drugs 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 2
239000000463 material Substances 0.000 claims description 2
229940079593 drug Drugs 0.000 abstract description 7
229940123445 Tricyclic antidepressant Drugs 0.000 abstract description 3
239000003029 tricyclic antidepressant agent Substances 0.000 abstract description 3
201000002491 encephalomyelitis Diseases 0.000 abstract 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 7
239000002899 monoamine oxidase inhibitor Substances 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
239000002858 neurotransmitter agent Substances 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
208000002193 Pain Diseases 0.000 description 5
230000036407 pain Effects 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
206010025482 malaise Diseases 0.000 description 4
210000002569 neuron Anatomy 0.000 description 4
206010021639 Incontinence Diseases 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
208000008238 Muscle Spasticity Diseases 0.000 description 3
239000002243 precursor Substances 0.000 description 3
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
208000018198 spasticity Diseases 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
102000010909 Monoamine Oxidase Human genes 0.000 description 2
108010062431 Monoamine oxidase Proteins 0.000 description 2
208000007101 Muscle Cramp Diseases 0.000 description 2
208000003435 Optic Neuritis Diseases 0.000 description 2
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 2
208000005392 Spasm Diseases 0.000 description 2
229930003779 Vitamin B12 Natural products 0.000 description 2
INQLNSVYIFCUML-QZTLEVGFSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=N1 INQLNSVYIFCUML-QZTLEVGFSA-N 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
230000006872 improvement Effects 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
208000035824 paresthesia Diseases 0.000 description 2
229960000964 phenelzine Drugs 0.000 description 2
239000003772 serotonin uptake inhibitor Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960004799 tryptophan Drugs 0.000 description 2
239000011715 vitamin B12 Substances 0.000 description 2
235000019163 vitamin B12 Nutrition 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
208000003164 Diplopia Diseases 0.000 description 1
206010013887 Dysarthria Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
201000011252 Phenylketonuria Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229960001393 dosulepin Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000004867 hydroxocobalamin Nutrition 0.000 description 1
239000011704 hydroxocobalamin Substances 0.000 description 1
229960001103 hydroxocobalamin Drugs 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000007108 local immune response Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
206010029864 nystagmus Diseases 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
229940053544 other antidepressants in atc Drugs 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
208000026473 slurred speech Diseases 0.000 description 1
IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000001148 spastic effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000018405 transmission of nerve impulse Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Fodder In General (AREA)
Control Of Indicators Other Than Cathode Ray Tubes (AREA)
Control Of El Displays (AREA)

NO19971539A 1994-10-05 1997-04-04 Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform NO314486B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9420116A GB9420116D0 (en)	1994-10-05	1994-10-05	A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en)	1995-04-26	1995-04-26	A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product
PCT/GB1995/002361 WO1996011009A1 (en)	1994-10-05	1995-10-05	Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound

Publications (3)

Publication Number	Publication Date
NO971539L NO971539L (no)	1997-04-04
NO971539D0 NO971539D0 (no)	1997-04-04
NO314486B1 true NO314486B1 (no)	2003-03-31

Family

ID=26305745

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19971539A NO314486B1 (no)	1994-10-05	1997-04-04	Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform

Country Status (19)

Country	Link
US (2)	US6096737A (de)
EP (1)	EP0784476B1 (de)
JP (1)	JPH10508583A (de)
AT (1)	ATE227124T1 (de)
AU (1)	AU710339B2 (de)
CA (1)	CA2200761C (de)
CZ (1)	CZ293873B6 (de)
DE (1)	DE69528773T2 (de)
DK (1)	DK0784476T3 (de)
ES (1)	ES2184808T3 (de)
FI (1)	FI116659B (de)
HU (1)	HU225493B1 (de)
IS (1)	IS1956B (de)
NO (1)	NO314486B1 (de)
NZ (1)	NZ293642A (de)
PL (1)	PL181802B1 (de)
PT (1)	PT784476E (de)
SK (1)	SK281932B6 (de)
WO (1)	WO1996011009A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0942751B1 (de) *	1996-07-05	2002-09-25	The WWK Trust	Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
GB9617990D0 (en) *	1996-08-29	1996-10-09	Scotia Holdings Plc	Treatment of pain
EP0835660A1 (de) *	1996-10-14	1998-04-15	Gaston Edmond Filomena Merckx	Zusammensetzungen enthaltend Methylcobalamin für die Behandlung von Muliple Sklerosis oder andere demyleinisierende Krankheiten
US7232830B2 (en) *	1998-06-26	2007-06-19	Elaine A Delack	Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) *	1999-02-24	1999-04-21	Worsley Andrew P	Composition for the treatment of pain
GB9906808D0 (en) *	1999-03-24	1999-05-19	Kilgowan Limited	Formulation for treatment of pain
GB2355191A (en) *	1999-10-12	2001-04-18	Laxdale Ltd	Combination formulations for fatigue, head injury and strokes
CA2774959C (en) *	2000-08-04	2016-05-31	Dmi Biosciences, Inc.	Method of using diketopiperazines and composition containing them
US8394813B2 (en)	2000-11-14	2013-03-12	Shire Llc	Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) *	2001-04-05	2002-10-10	Pfizer Inc.	Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en)	2002-07-10	2002-08-21	Arachnova Therapeutics Ltd	New therapeutic use
US7169752B2 (en) *	2003-09-30	2007-01-30	New River Pharmaceuticals Inc.	Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) *	2002-03-14	2004-12-21	Duane Bennett	Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
US7575929B2 (en)	2002-10-02	2009-08-18	Dmi Life Sciences, Inc.	Diagnosis of multiple sclerosis with diketopiperazines
JP2006517969A (ja) *	2003-02-14	2006-08-03	コンビナトアールエックスインコーポレーティッド	免疫炎症性障害の治療のための組み合わせ療法
CN103191409A (zh)	2003-05-15	2013-07-10	Dmi生物科学公司	T-细胞介导的疾病的治疗
GB0313630D0 (en) *	2003-06-12	2003-07-16	Wwk Trust The	Compositions for the enhanced treatment of depression
US20050192261A1 (en) *	2003-09-15	2005-09-01	Jost-Price Edward R.	Methods and reagents for the treatment of immunoinflammatory disorders
US20110136742A1 (en) *	2006-02-24	2011-06-09	Travis Mickle	Antidepressant prodrugs
US8217047B2 (en) *	2008-05-27	2012-07-10	Dmi Acquisition Corp.	Therapeutic methods and compounds
WO2011011594A2 (en) *	2009-07-23	2011-01-27	Shriners Hospitals For Children	Intracellular toll-like receptors pathways and axonal degeneration
CA2810844C (en)	2010-09-07	2017-03-21	Dmi Acquisition Corp.	Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
CA2846598C (en)	2011-10-10	2019-12-10	Ampio Pharmaceuticals, Inc.	Treatment of degenerative joint disease
EP2765968A4 (de)	2011-10-10	2015-01-21	Ampio Pharmaceuticals Inc	Implantierbare medizinprodukte mit erhöhter immuntoleranz sowie verfahren zur herstellung und implantation
HK1198812A1 (en)	2011-10-28	2015-06-12	Ampio Pharmaceuticals, Inc.	Treatment of rhinitis
EA201500943A1 (ru)	2013-03-15	2016-08-31	Ампио Фармасьютикалс, Инк.	Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
CA2958080A1 (en)	2014-08-18	2016-02-25	Ampio Pharmaceuticals, Inc.	Treatment of joint conditions
US11389512B2 (en)	2015-06-22	2022-07-19	Ampio Pharmaceuticals, Inc.	Use of low molecular weight fractions of human serum albumin in treating diseases
WO2017085437A1 (en)	2015-11-19	2017-05-26	The Wwk Trust	Combinations for the treatment of dementia, and the enhancement of cognitive function
US20190262353A1 (en) *	2016-10-25	2019-08-29	Uti Limited Partnership	Treatment for progressive multiple sclerosis
WO2018200381A1 (en)	2017-04-25	2018-11-01	Temple Otorongo Llc	Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (de) *	2017-07-18	2019-01-23	Centre National De La Recherche Scientifique	Verfahren zur reinigung von proteinen mit einer tubulin-carboxypeptidase-aktivität und peptidbasierten inhibitoren davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1497306A (en) *	1975-07-03	1978-01-05	Leo Ab	Preparation of lofepramine and its hydrochloride
GB2082910A (en) *	1980-08-28	1982-03-17	Berk Pharmaceuticals Ltd	Anti-depressant compositions
US4409243A (en) *	1981-11-09	1983-10-11	Julian Lieb	Treatment of auto-immune and inflammatory diseases
GB2129299A (en) *	1982-11-09	1984-05-16	Alec James Coppen	Pharmaceutical compositions
DE3519687A1 (de) *	1985-06-01	1986-12-04	Veit Arend	Aminosaeuren enthaltendes arzneimittel
US4650789A (en) *	1985-10-15	1987-03-17	Commonwealth Medical Corporation Of America	Method and composition for increasing production of serotonin
US4843071A (en) *	1986-12-05	1989-06-27	Serotonin Industries Of Charleston	Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) *	1992-02-12	1998-09-24	Kragler Peter	Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

1995
- 1995-10-05 DE DE69528773T patent/DE69528773T2/de not_active Expired - Lifetime
- 1995-10-05 WO PCT/GB1995/002361 patent/WO1996011009A1/en not_active Ceased
- 1995-10-05 HU HU9702373A patent/HU225493B1/hu not_active IP Right Cessation
- 1995-10-05 AT AT95933488T patent/ATE227124T1/de not_active IP Right Cessation
- 1995-10-05 CZ CZ1997995A patent/CZ293873B6/cs not_active IP Right Cessation
- 1995-10-05 PL PL95319830A patent/PL181802B1/pl not_active IP Right Cessation
- 1995-10-05 EP EP95933488A patent/EP0784476B1/de not_active Expired - Lifetime
- 1995-10-05 JP JP8512415A patent/JPH10508583A/ja active Pending
- 1995-10-05 CA CA002200761A patent/CA2200761C/en not_active Expired - Fee Related
- 1995-10-05 US US08/817,086 patent/US6096737A/en not_active Expired - Lifetime
- 1995-10-05 SK SK438-97A patent/SK281932B6/sk not_active IP Right Cessation
- 1995-10-05 PT PT95933488T patent/PT784476E/pt unknown
- 1995-10-05 NZ NZ293642A patent/NZ293642A/xx not_active IP Right Cessation
- 1995-10-05 ES ES95933488T patent/ES2184808T3/es not_active Expired - Lifetime
- 1995-10-05 DK DK95933488T patent/DK0784476T3/da active
- 1995-10-05 AU AU36126/95A patent/AU710339B2/en not_active Ceased
1997
- 1997-03-26 FI FI971290A patent/FI116659B/fi active IP Right Grant
- 1997-03-26 IS IS4454A patent/IS1956B/is unknown
- 1997-04-04 NO NO19971539A patent/NO314486B1/no not_active IP Right Cessation
2000
- 2000-06-01 US US09/584,401 patent/US6569850B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT784476E (pt)	2003-03-31
ATE227124T1 (de)	2002-11-15
JPH10508583A (ja)	1998-08-25
AU3612695A (en)	1996-05-02
FI971290L (fi)	1997-06-02
CA2200761A1 (en)	1996-04-18
US6096737A (en)	2000-08-01
NO971539L (no)	1997-04-04
DE69528773T2 (de)	2003-09-04
ES2184808T3 (es)	2003-04-16
NZ293642A (en)	1998-10-28
PL319830A1 (en)	1997-09-01
NO971539D0 (no)	1997-04-04
DE69528773D1 (de)	2002-12-12
WO1996011009A1 (en)	1996-04-18
CA2200761C (en)	2008-02-26
EP0784476A1 (de)	1997-07-23
CZ99597A3 (en)	1997-11-12
FI116659B (fi)	2006-01-31
AU710339B2 (en)	1999-09-16
SK281932B6 (sk)	2001-09-11
PL181802B1 (en)	2001-09-28
FI971290A0 (fi)	1997-03-26
HU225493B1 (en)	2007-01-29
US6569850B1 (en)	2003-05-27
DK0784476T3 (da)	2003-03-17
HUT77380A (hu)	1998-04-28
IS1956B (is)	2004-11-15
CZ293873B6 (cs)	2004-08-18
IS4454A (is)	1997-03-26
EP0784476B1 (de)	2002-11-06
SK43897A3 (en)	1998-08-05

Legal Events

Date	Code	Title	Description
2013-05-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO314486B1 (no)	2003-03-31	Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform
Kita et al.	2000	Drugs used to treat spasticity
Detke et al.	2002	Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
Mavissakalian et al.	1989	Imipramine dose-response relationship in panic disorder with agoraphobia: Preliminary findings
Larrison-Faucher et al.	2004	Nicotine reduces antisaccade errors in task impaired schizophrenic subjects
Greene et al.	1992	Baclofen in the treatment of idiopathic dystonia in children
Fabbri et al.	2018	Adjunctive Therapies in Parkinson’s Disease: How to Choose the Best Treatment Strategy Approach.
O’Brien et al.	1996	Spasticity after stroke: epidemiology and optimal treatment
Cross et al.	2020	A perspective on cannabinoids for treating epilepsy: do they really change the landscape?
Clanet et al.	2000	The management of multiple sclerosis patients
CN107405335A (zh)	2017-11-28	治疗肌萎缩侧索硬化和神经病的方法
La Spina et al.	2001	Gabapentin in painful HIV‐related neuropathy: a report of 19 patients, preliminary observations
US11369619B2 (en)	2022-06-28	Composition for curing migraine headaches
Li et al.	2003	Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study
SOLYOM et al.	1989	Trazodone treatment of bulimia nervosa
Sahoo et al.	2018	Rehabilitation of organophosphate induced delayed polyneuropathy
Jankovic	2005	Dystonia
Ross et al.	2009	Variable angle of strabismus related to timing of opiate ingestion
Quazi	2023	The Study of Drug Utilisation Evaluation of Benzodiazepine Derivatives and Antipsychotic Drugs Prescribed in Tertiary Care Hospital
FURMANSKI	1954	BAL therapy in infectious and metabolic neuropathies
Bradford et al.	2002	Therapy: Recent Progress in Clinical Applications and Research in Fibromyalgia--Part 3
Singh et al.	0	An Ayurvedic approach in the management of diabetic neuropathy-a case report
Klenerova et al.	2002	Effect of restraint stress on the memory of Wistar rats in the passive avoidance task; time relationship between footshock and stress applications
Engel et al.	2012	Aging of the human neuromuscular system: patient vignettes
Meara	2000	The Drug Treatment of